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Abstract Asmuch as the cellular viability is important for the
living organisms, the elimination of unnecessary or damaged
cells has the opposite necessity for the maintenance of homeo-
stasis in tissues, organs and the whole organism. Apoptosis, a
type of cell death mechanism, is controlled by the interactions
between several molecules and responsible for the elimination
of unwanted cells from the body. Apoptosis can be triggered
by intrinsically or extrinsically through death signals from the
outside of the cell. Any abnormality in apoptosis process can
cause various types of diseases from cancer to auto-immune
diseases. Different gene families such as caspases, inhibitor of
apoptosis proteins, B cell lymphoma (Bcl)-2 family of genes,
tumor necrosis factor (TNF) receptor gene superfamily, or p53
gene are involved and/or collaborate in the process of apopto-
sis. In this review, we discuss the basic features of apoptosis
and have focused on the gene families playing critical roles,
activation/inactivation mechanisms, upstream/downstream ef-
fectors, and signaling pathways in apoptosis on the basis of
cancer studies. In addition, novel apoptotic players such as
miRNAs and sphingolipid family members in various kind
of cancer are discussed.
Keywords Intrinsic/extrinsic pathway . Bcl-2 . Caspase .
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Introduction
The main goal for a cell is to stay alive during the lifetime.
Holding the key of proliferation events as much as death
mechanism has vital importance for the cells to keep the bal-
ance between living and death cells in the body. As one of the
cellular death mechanisms, apoptosis, also known as pro-
grammed cell death, can be defined as the process of a proper
death of any cell under certain or necessary conditions.
Apoptosis is a part of natural homeostatic mechanism to keep
the number of the cells constant in an organism and helps the
tissue to eliminate increasing number of unwanted/unneeded
cells that are damaged or no longer manageable during devel-
opment, growth or aging [1]. It also plays crucial roles in
early development and differentiation of the embryo in order
to generate a full and decent organism. Although the term of
Bapoptosis^was firstly used by Kerr et al. in 1972 to identify a
distinguished type of cell death, the first description and un-
derstanding of the programmed mechanisms of apoptosis was
derived from the studies on the development of the nematode
Caenorhabtidis elegans in 1999 [2, 3].
Apoptosis is a defense mechanism against damaged,
stressed, or stimulated cells by any agents to prevent accumu-
lation of non-functional cells in the tissues. If apoptosis is not
be mediated properly in unwanted cells, the mutations could
continue to accumulate in the cells that eventually could lead
to generation of cancer and other diseases such as auto-
immune diseases, AIDS, or some of neurodegenerative disor-
ders [4]. However, apoptosis is the best defined and well-
understood Bprogrammed^ type of cell death; there are many
different types of cellular death mechanisms such as
pyroptosis, necrosis, or autophagy, and some others might
not yet be discovered [5, 6]. Apoptosis regulatory pathways,
including a number of gene families, orchestrate the specific
morphological and biochemical changes in the cells during the
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process. We touched on these significant chances briefly and
focused on the genes involved in apoptosis with details.
Morphological and biochemical processes of apoptosis
Many biochemical events and a series of morphological
changes occur at the early stage and increasingly continue till
the end of apoptosis process. Some of the changes such as cell
shrinkage, chromatin condensation, or nuclear differences
could be observed by microscopic techniques [1, 7].
Morphological event cascade including cytoplasmic filament
aggregation, nuclear condensation, cellular fragmentation,
and plasma membrane blebbing finally results in the forma-
tion of apoptotic bodies. All the morphological hallmarks of
apoptosis can be gathered under three headings; (i) the changes
occur in nucleus; (ii) cell membrane and cytosolic changes; (iii)
those happen in mitochondria [1, 8]. Chromatin condensation,
DNA fragmentation, and nuclear fragmentation are the nucle-
ar changes that could be observed with light and fluorescence
microscopy during apoptosis. The apoptotic cell loses its as-
sociation with other cells at initiation stage of the process by
different signals breaking the connection. This separation
followed by apoptotic body formation and resulted in
blocking the inflammatory reaction of the cells, since they
package their ingredient and do not release any contaminant
outside the cell. Then, the buddies are rapidly phagocytized by
other neighbor cells and these absorber cells do not produce
any signal that causes any inflammatory response. Also, mi-
tochondria play an important role by interacting with many
different apoptotic/anti-apoptotic proteins and releasing signal
molecules [9, 10].
Chromatin condensation and nuclear fragmentation are the
major modifications observed in the nucleus, eventually
resulting in pyknosis (chromatin condensates irreversibly that
signs cell death) and followed by karyorrexis (nuclear frag-
mentation, the last event in nucleus during apoptosis) [11].
The fragmentation of double-stranded DNA into 180–200
bp sequences in length by the help of caspase proteins is also
another essential hallmark of nuclear events during apoptosis.
Caspases are responsible for DNA repair during replication as
well as the termination stage of apoptosis. They are also in-
volved in the fragmentation in apoptosis together with DNA
fragmentation factors (DFFs) and endonucleases. Most of the
nuclear changes of apoptosis observed by electron microsco-
py or even light microscopy make the apoptosis process to be
determined easily [11, 12].
As soon as the apoptosis is initiated in the cells, they lose
the connection between the neighboring cells; membrane
shrinks and the cell packs its cytosolic ingredients into apo-
ptotic buddies. The apoptotic buddies will be eliminated by
phagocytotic cells that recognize phosphatidylserine, which is
normally located in the inner side of the cell membrane and
flips to the outer membrane during apoptosis [13]. At the same
time, the cytoplasmic scaffold proteins and cell junction pro-
teins such as actin,β-catenin, spectrin, or Gas2 are deactivated
by cleavage and the cell loses its integrity by the function of
caspases [14].
Mitochondria have complex and important roles by provid-
ing various pro-apoptotic signals, creating a downstream cas-
cade of apoptosis activation. The balance between the pro-
apoptotic and anti-apoptotic molecules keeps the cellular ho-
meostasis stable and determines the cell fate, which is either
apoptosis or proliferation. Mitochondria have a leading role in
releasing a number of important apoptosis inducing molecules
including cytochrome c, SMAC, apoptosis-inducing factor, or
endonuclease G as a result of permeabilization of mitochon-
drial membrane. Permeabilization is triggered by pro-
apoptotic B cell lymphoma (Bcl)-2 family proteins, while
the integrity of mitochondrial membrane is maintained by
anti-apoptotic members of Bcl-2 family [10, 15, 16].
Several biochemical changes such as protein modifica-
tions/degradations, DNA and chromatin deteriorations, and
synthesis of cell surface markers form morphological process
during apoptosis. Caspases are mainly responsible for these
changes with their extensive capabilities to cleave certain mol-
ecules from one or more specific points, causing degradation
and inactivation of target protein. Moreover, they can also
inhibit the negative regulatory domains of specific proteins,
which leads to the activation of subjected molecule [17, 18].
They are also involved in DNA fragmentation process.
Intrinsic and extrinsic apoptotic pathways
Apoptosis can be stimulated by two different pathways: (i)
intrinsic pathway (or mitochondria) that mainly occurs via
release of cytochrome c from the mitochondria, which acti-
vates different caspases as downstream signals, and (ii) extrin-
sic pathway when Fas death receptor is activated by a signal
coming from the outside of the cell. After the activation of
different intermediate molecules by signaling cascade, both of
the pathways meet up at the final caspase activation step and
commonly lead to cleavage of different proteins [19] (Fig. 1).
Intrinsic pathway
The intrinsic pathway of apoptosis is independent from a re-
ceptor signaling, and mitochondria-associated stimuli create
an intracellular signaling. The inner activation of this pathway
makes the cell undergo apoptosis in either a positive or nega-
tive manner. The positive stimuli (e.g., toxic materials, viral
infections, and radiations) directly activate all the mediators
for apoptosis, whereas negative stimuli (loss of growth fac-
tors, different cytokines, or certain type of hormones) work in
contrast to positive one and eliminate the factors that suppress
apoptosis in the cells and cause apoptotic activation [1, 20]. In
addition to different infections or cytokine-mediated intrinsic
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apoptosis activation, DNA damage also majorly induces apo-
ptosis as a protectionmechanism of the cells that do not let self
to continue proliferation with an imperfect DNA sequence.
DNA damage or any other type of apoptosis stimuli basically
causes the changes in the trans-membrane potential of mito-
chondria, which result in the release of pro-apoptotic proteins
into the cytoplasm.
Cytochrome c, Smad, or high-temperature requirement
protein A2 (HtrA2)/Omi are a group of pro-apoptotic mole-
cules released from mitochondria and cause the activation of
caspase protein cascade [21, 22]. Cytochrome c interacts with
Apaf-1, resulting in the formation of Bapoptosome^ complex,
which activates pro-caspase-9. After active caspase-9 acti-
vates caspase-3, the final cascade is become activated and
nucleus will be fragmented together with the breaking of nu-
clear membrane [23]. This stage is the initial event for extrin-
sic and intrinsic pathways of apoptosis, where caspase-3
cleaves the different proteins such as kinases, DNA control
proteins, cytoskeletal proteins, or inhibitor of endonucleases.
DNA condensation, membrane blebbing, and all the morpho-
logical changes are regulated by caspases as a common mech-
anism for both intrinsic and extrinsic trigger [17].
On the other hand, another group of molecules released by
mitochondria including endonuclease G or AIF are also pro-
apoptotic proteins but involved in the process at the later
stages. These molecules are trans-located into the nucleus
where they first cause an elementarily DNA fragmentation
and chromatin condensation which is defined as Bstage 1,^
Fig. 1 Twomain apoptotic pathways; intrinsic and extrinsic pathways. In
the extrinsic pathway, interaction between the death receptors and their
ligands initiates the pathway, resulting in caspase 8 activation. This
activation can be inhibited by cFLIP. Caspase 8 can directly induce
apoptosis or activates caspase 3 or Bid, which lead to apoptosis. On the
other hand, intrinsic pathway can be initiated by DNA damage. As a
response, the cells can trigger apoptosis through mitochondrial pathway,
which starts with the activation of the pro-apoptotic member of the Bcl-2
family, Bax. Anti-apoptotic proteins inhibiting the action of Bax are
located on the membrane of the mitochondria such as Bcl-2 and Bcl-
XL. Release cytochrome c, APAF-1 complex, and pro-caspase9 can be
gathered in the cytosol, which is called apoptosome. The formation of this
complex will result in the activation of caspase 9 followed by the
transformation of pro-caspase-3 to caspase 3, which is the last step for
apoptosis. The cross talk between extrinsic and intrinsic pathways of
apoptosis is regulated by Bid, a pro-apoptotic member of Bcl-2 family.
The cleavage of Bid ismediated by caspase 8, which induces apoptosis by
releasing cytochrome c release from the mitochondria
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and an advanced condensation and DNA fragmentation by the
help of caspase-3 at later stage is called as Bstage 2^ [24].
All the intrinsic apoptosis events are primarily controlled by
Bcl-2 family of proteins and p53 tumor suppressor protein
which is majorly involved in the activation of Bcl-2 family
proteins. Themembers of Bcl-2 protein family can act as either
pro-apoptotic (Bax, Bak, Bid, Bim, Puma, Noxa, Bad, and
Blk) or anti-apoptotic (Bcl-2, Bcl-XL, Bcl-X, and BAG) and
also determine themembrane integrity ofmitochondria and are
involved in the process of cytochrome c release [1, 25].
Extrinsic pathway
Apoptosis triggered by extrinsic pathway is primarily mediat-
ed by signaling through membrane-bound death receptors that
belong to tumor necrosis factor (TNF) gene superfamily. The
initial signal is provided by the interactions between the li-
gands and cell membrane death receptors such as Fas ligand/
FasR, TNF/TNF R1, Apo2L/DR4, or TNF-related apoptosis-
inducing ligand (TRAIL) R1, which is resulted in ligation of
death domains of these receptors [26]. Binding of Fas ligand
to its receptor induces the binding of adaptor protein, Fas-
associated death domain (FADD), while TNF/tumor necrosis
factor receptor (TNFR) interaction causes the binding of
TNFR-associated death domain (TRADD), which is resulted
in pro-caspase-8 activation. Pro-caspase-8 is activated auto-
catalytically by the help of death-inducing signaling complex
(DISC). Active caspase-8 either induce Bid, thus intrinsic
pathway also become involved and activated with an outside
signal, or caspase-3 and caspase-7 and the activation process
of apoptosis is terminated with the same final pathway as
intrinsic stimuli does [1, 19, 27, 28]. Bid is the pro-apoptotic
member of Bcl-2 family, exhibiting a common molecule be-
tween intrinsic and extrinsic pathways of apoptosis. Caspase-
8 causes the cleavage and myristoylation of cytoplasmic Bid
protein, leading to its movement through mitochondria. Then,
apoptosome formation is induced by cytochrome release via
Bak and Bax molecules [29].
The extrinsic activation of apoptosis can also be inhibited
via two different ways. The one is binding of FLICE-like
inhibitory protein (cFLIP) to FADD and pro-capase-8 and
blocking their activity, and the other way is inhibition of
caspase-8 biogenesis by a protein named Toso which is firstly
described in T cells [30, 31].
In the next sessions, we will discuss all the gene families
involved in intrinsic or extrinsic pathways of apoptosis with
their main player and their functions.
Caspase family members
Caspase family comprise conserved cysteine aspartic-specific
proteases, and members of caspase family are considerably
crucial in the regulation of apoptosis [32]. In C. elegans,
Ced-3 was reported to be essential for the cell death, which
is mainly conducted by the caspase Ced-3, Ced-4 activating
Ced-3, and Ced-9 inhibiting apoptosis [33, 34]. There are 14
different caspases in mammals, and they are basically classi-
fied as the initiators including caspase-2, -8, -9, and -10; and
the effectors including caspase-3, -6, -7, and -14; and also the
cytokine activators including caspase-1, -4, -5, -11, -12, and -
13 [35, 36]. Structurally, while initiator caspases have long N-
terminal pro-domain known as caspase recruitment domains
(CARDs) including more than 90 amino acids, effector
caspases have shorter sequences known as death effector do-
main (DED) including 20–30 amino acids. Since caspases
firstly synthesized as zymogens, they are subsequently acti-
vated during the apoptotic process. While initiator caspases
are self-activated, effector caspases are activated by initiator
caspases via internal cleavages [37]. Rather than apoptosis,
most of caspase family members are functional in cellular
proliferation, survival, and inflammation, whereas some of
them are essential for apoptosis [38, 39].
Caspase-1, the first identified caspase, is interleukin-1b
processing enzyme (ICE), and it is known as Ced-3 homo-
logue [40]. Caspase-1 is involved in cytokine activator group
of caspase family since inflammatory cytokines, pro-IL-1b
and pro-IL-18, are the main substrates for caspase-1 [39].
While caspase-1 is not essential for apoptotic signaling, it is
essential in inflammation process [41].
The second identified caspase, caspase-2, containing
CARD, plays important roles in DNA damage-, metabolic
abnormality-, and ER stress-induced apoptosis [42].
Caspase-2 is known as a substrate for both caspase-3 and
caspase-8 [43, 44]. Caspase-2 activation comprises the forma-
tion of PIDDosome complex including RIP-associated ICH-1/
ECD3 homologous protein with death domain (RAIDD) that
have CARD and death domain (DD) and p53-induced protein
with death domain (PIDD) [45]. Functional properties of
caspase-2 have still not been clarified thoroughly.
Caspases-3, -6, and -7 are involved in the effector caspase
group, and they act in a similar manner in the apoptotic pro-
cess [46]. Caspase-3 is activated via both extrinsic and intrin-
sic apoptotic pathways [47]. Despite there are limited infor-
mation about caspase-6 and -7 rather than caspase-3, it is
known that while caspase-3 suppression results in the inhibi-
tion of apoptosis, suppression of caspase-6 and -7 do not sig-
nificantly affect the apoptotic process [48]. Furthermore,
caspase-3 was reported to be crucial for PARP cleavage and
DNA fragmentation which are hallmarks of apoptosis [49].
However, some studies showed that under the conditions that
both caspase-3 and caspase-7 were knocked out, the cells
could undergo cell death in an alternative manner via necrosis.
Studies with caspase-3/caspase-7 double-knockout thymo-
cytes and mouse embryonic fibroblasts showed that thymo-
cytes remain sensitive to Fas-mediated apoptosis, whereas fi-
broblasts become resistant [49, 50].
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Functionally well-known member of caspase family, cas-
pase-8, is crucial factor for TNF-induced extrinsic apoptotic
pathway [51]. Pro-caspase-8 is recruited to DISC by FADD,
and dimerization or trimerization triggers pro-caspase-8 acti-
vation via reciprocal cleavage. Caspase-8, in turn, cleaves and
activates caspase-3, -7, Bid, and also NF-kB [52, 53].
Caspase-8 activation is regulated by cFLIP that is structurally
homologous to caspase-8 but does not have caspase activity
[54]. FLIPS, the short isoform of cFLIP, controls the DISC
formation in a negative manner. However, the long isoform
of cFLIP, FLIPL, has reciprocal effect on DISC formation and
caspase-8 activity. While some studies reported FLIPL to be
inducer of DISC formation, some reports showed that it could
be an inhibitor [55, 56]. Inhibitor and inducer effects of FLIPL
on caspase-8 activity depend on FLIPL levels. At low concen-
trations, generation of heterodimers between FLIPL and pro-
caspase-8 or pro-caspase-10 induces their activity. However,
at higher levels of FLIPL, caspase-8 activation diminishes and
NF-kB activation increases [57, 58].
Caspase-9, the initiator caspase, is an important factor for
the generation of apoptosome complex in the mitochondrial
pathway. Once cytochrome c is released from the mitochon-
dria, it binds to Apaf1 which is the receptor for cytochrome c
in the cytoplasm [59]. Cytochrome-c and Apaf-1 generate
apoptosome, and then, pro-caspase-9 binds to Apaf-1.
Afterward, pro-caspase-9 is activated via reciprocal cleavage,
and by this way, apoptosome complex also become activated.
Then, caspase-3 is cleaved and activated via caspase-9 found
in the active apoptosome complex [60].
Inhibitors of apoptosis proteins and inhibitors of apoptosis
protein antagonists
Inhibitors of apoptosis proteins (IAPs) were firstly discovered
in Baculovirus as gene products. All IAPs have baculovirus
IAP repeats (BIRs) that composed of one or more zinc finger
motifs [61]. The first identified IAP, OpIAP, inhibits pro-
caspase cleavage and activation rather than direct inhibition
of caspase activity [62]. NAIP, the first identified mammalian
IAP, was reported to be related to the generation of immune
response against bacterial infection. Hence, it is not directly
correlated with caspase inhibition [63].
Survivin/BIRC5, another identified mammalian IAP, was
firstly reported as caspase inhibitor, but now, it is known that
survivin does not directly inhibit caspase activity. Mechanism
of action of survivin, bearing one BIR domain, is to assemble
with centromeres and p21Waf1 at the beginning of mitosis
[64, 65].
XIAP/BIRC4, the mostly clarified mammalian IAP, has
three BIR domains and a RING domain; it is located on X
chromosome; and also, it is quite effective in apoptosis inhi-
bition via inhibiting caspase activity [66]. Mainly, caspase-3
and caspase-7 can be inhibited by XIAP via inserting a residue
of aspartic acid into the caspase active region [67].
Additionally, XIAP can also inhibit caspase-9 activity via
binding the third BIR to the N-terminus of pro-caspase-9,
resulting in the prevention of caspase-9 dimerization [68].
Similarly, another mammalian IAPs, cIAP1/BIRC2, and
cIAP2/BIRC3 have three BIR domains and a RING domain
in their structures [63]. Rather than inhibiting directly caspase
activity, they inhibit apoptosis indirectly. They can bind IAP
inhibitor, second mitochondrion-derived activator of caspase/
direct inhibitor of apoptosis-binding protein with low pI
(SMAC/DIABLO), trigger NF-kB and MAPK activity, and
also they can trigger proteasomal degradation of caspases
[69].
Bruce/BIRC6, a member of IAP family, is mainly found in
secretory organs, testis, lymphatic cells, and brain. Similar to
survivin, Bruce located at the outer membrane of the trans-
Golgi network bears only one BIR domain. Bruce can inhibit
caspase-3, -6, -7, -8, and -9, and also, it can trigger the
proteasomal degradation of SMAC/DIABLO. Many studies
showed that Bruce is upregulated in ovarian and brain cancer
cell lines, resulting in development of resistance against apo-
ptotic agent [70].
IAP antagonists, SMAC/DIABLO, HtrA2/Omi, and
XIAP-associated factor 1 (XAF1) are known as potent inhib-
itors of IAPs. SMAC/DIABLO bears a mitochondrial
targeting signal (MTS) at N-teminus, and it become mature
after the MTS cleavage [21]. Once apoptosis is triggered,
SMAC/DIABLO is delivered into the cytosol, and
SMAC/DIABLO homodimers bind to IAPs via its Ala-Val-
Pro-Ile sequence in N-terminal domain [71]. Interaction of
SMAC/DIABLO with XIAP via the second and third BIRs
results in caspase-3 and caspase-9 release [72]. It was reported
that SMAC is overexpressed in several types of solid tumors
such as colon, stomach, prostate, ovary, and lung cancers [73].
Likewise, HtrA2/Omi delivery is triggered via apoptotic in-
duction and then, it binds to IAPs through its IAP-binding
motif (IBM) [74]. XAF1, the other potent IAP antagonist,
binds to BIR domains of IAPs such as XIAP, cIAP1, and
cIAP2 and by this way, promotes apoptosis [75]. A study
suggesting XAF1 as a prognostic marker for colon cancer
showed that XAF1 is overexpressed in colon cancer cells as
compared to adenoma cells which are benign [76].
Bcl-2 family members
Bcl-2 family members, which play important roles in regulat-
ing apoptotic signaling, are divided into three subfamilies in-
cluding (i) pro-survival subfamily members (Bcl-2, BclXL,
BclW, MCL1, and BFL1/A1), (ii) BH3-only subfamily mem-
bers (Bad, Bim, Noxa, and Puma9), and (iii) pro-apoptotic
mediator subfamily members (Bax and Bak) [77, 78].
Basically, all of the members of Bcl-2 family share typical
characteristic functions; (i) they dimerize with other members
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of Bcl-2 family, (ii) they contribute to the regulation of mito-
chondrial homeostasis by binding proteins, and (iii) they con-
tribute to outer mitochondrial membrane pore formation [79].
The members of BH3-only subfamily members become
activated under stress conditions like growth factor depriva-
tion and DNA damage. Active BH3-only proteins, in turn,
inactivate members of pro-survival subfamily via binding that
promotes the activation of the members of pro-apoptotic sub-
family members. Active pro-apoptotic subfamily members,
Bak and Bax, then provide cytochrome c release from the
mitochondria through permeabilizing the outer mitochondrial
membrane [80].
In several types of human malignancies, the balance be-
tween the expression levels of Bcl-2 family genes is broken
down, and the equilibrium changes to the pro-survival sub-
family member direction. In this case, cancer cells can escape
from apoptotic signals and therefore develop resistance
against therapeutic agents [81, 82]. Additionally, Bcl-2 family
members are also considered in cancer therapy due to their
therapeutic potentials [83]. In the clinical trials, the BH3-only
mimetic agents targeting Bcl-2 are being investigated in order
to find alternative potent therapeutic approaches in several
types of malignancies [84–86].
TNF gene superfamily
One of the most important ways of triggering apoptosis is
mediated through death receptors (DRs), which are classified
in TNF superfamily including also ligands such as TNF,
TRAIL, and Fas ligand (FasL) [87]. The induction of apopto-
sis by these ligands is initiated by binding to their specific
membrane receptors [88, 89]. TNF superfamily is known to
comprise 19 ligands and 29 receptors that function in highly
different processes in the body including inflammation, apo-
ptosis, proliferation, and invasion [90]. Even though all mem-
bers of TNFR superfamily are generally trimeric type I trans-
membrane proteins and possess cysteine-rich extracellular
subdomains, they are actually different in their primary struc-
ture, which make them unique to recognize their ligand in a
specific and exclusive manner [91]. These DRs also contain a
homologous cytoplasmic cysteine-rich BDD^ which is respon-
sible for transmission of apoptotic signals from cell surface to
intracellular signaling pathways [92]. Because, adapter mole-
cules such as FADD and TRADD have these death domains
as well to interact with DRs. The ligands included in TNF
superfamily share a common extracellular TNF homology
domain (THD), which is involved in the formation of
homotrimers via non-covalent bonding [93]. The extracellular
domain of most TNF ligands undergoes proteolytic cleavage
to make a soluble ligand, even though they are synthesized as
type II trans-membrane proteins [93].
CD95 (DR2/Fas/APO-1), TNF receptor 1 (DR1/TNFR1),
TRAIL-R1 (DR4), and TRAIL-R2 (DR5) are the best
characterized DRs of which ligands are CD95 ligand
(CD95L/FasL), TNFα, lymphotoxin-α (these two bind to
TNFRI), and TRAIL (these two bind to TRAIL-R1 and
TRAIL-R2), respectively [94]. The genes encoding TNF su-
perfamily receptors and ligands are the scope of this part to-
gether with their significant contribution to apoptosis
specifically.
Fas cell surface death receptor and Fas ligand
The proteins encoded by Fas cell surface death receptor (FAS)
and Fas ligand (FASLG) genes are members of the TNF su-
perfamily. Fas also known as CD95/APO-1/DR2 is one of the
best studied DRs with molecular weight of 48 kDa. Fas gene
occupies about 25 kb on human chromosome 10 with nine
exons in which exon 6 codes for trans-membrane domain
[95]. This receptor containing a DD plays a crucial role in
the regulation of programmed cell death and is involved in
the pathogenesis of various malignancies such as cancer. On
the other hand, FasLG gene is located on human chromosome
1, which encodes a type II trans-membrane protein called
FasL (CD95L) present at the surface of activated immune
cells such as T cells and natural killer cells [93]. Therefore,
Fas/FasL interaction results in the elimination of infected and
transformed cells, which is generally used by immune cells to
avoid cancer development.
The interaction of Fas with FasL results in changes in the
conformation and aggregation of receptor on the plasmamem-
brane and triggers an initial signaling event through protein-
protein interactions. The main structural changes take place in
DD of receptor, which recruits FADD through its DD. Then,
FADD interacts with pro-caspase-8 and -10. After activation
of these caspases via auto-cleavage, they are released in the
cytosol as active caspases resulting in the apoptotic cell death.
The complex CD95/FADD/caspase-8/-10 is called DISC
stands for Bdeath-inducing signaling complex^ [96].
In the literature, there are various kinds of studies identify-
ing the roles of Fas/FasL in order to induce apoptosis in sev-
eral malignancies especially in cancer. Escaping from apopto-
tic stimuli is a very well known feature of cancer cells which
might developmultiple strategies to inhibit apoptotis mediated
by CD95. In a majority of cancer types from different origins,
somatic mutations in CD95 gene were found to be a common
way to trigger the development of resistance toward apoptosis.
For instance, 5′ region of CD95 gene was analyzed in terms of
somatic mutations in nodal diffuse large B cell lymphoma and
defined mutations were shown to be included in progression
of diseases due to inhibition of apoptosis [97]. Another com-
mon way to become resistant to CD95-induced apoptosis is
the regulation of surface expression of receptor [98]. In a study
performed by Ivanow et al. (2006) [98], the treatment of mel-
anoma cells having increased surface expression of Fas recep-
tor with soluble FasL resulted in the induction of apoptosis.
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CD95-mediated apoptosis can also be blocked by decreasing
expression of FADD or caspase-8 [99, 100].
In a recent study, the effect of a toxic steroid on human
bladder cancer cells was found to be related to increased ex-
pressions of Fas and FasL in vitro and in vivo at both messen-
ger RNA (mRNA) and protein levels [101]. Zhong et al.
(2015) [102] showed that the mechanism of resistance to
Fas-mediated apoptosis in human hepatocellular carcinoma
cells (HCCs) and overexpression of oxysterol-binding pro-
tein-related protein 8 (ORP8) which is normally downregulat-
ed in HCC was found to induce apoptosis by upregulating
FasL.
TRAIL
TRAIL (also called as APO2 ligand) is a type II trans-
membrane protein and processed proteolytically at the cell
surface to form a soluble ligand. TRAIL is grouped into the
TNF cytokine family, which was discovered based on its ex-
tracellular domain sequence homology with CD95L and TNF
[103]. TRAIL-mediated apoptosis takes place after its binding
to its DD containing receptors, TRAIL receptor 1 (death re-
ceptor 4, DR4), and TRAIL receptor 2 (death receptor 5, DR5)
[104]. There are also three other TRAIL receptors, which do
not possess apoptotic ability and function as decoys. Decoy
receptors 1 (DcR1) and 2 (DcR2) are expressed on the cell
surface similar to DR4 and DR5. Even though their extracel-
lular and ligand-binding domains show significant homology
to DR4 and DR5 and are fully functional, they lack of func-
tional intracellular DD [105]. Therefore, increased expression
of either DcR1 or DcR2 provides resistance against TRAIL-
induced apoptosis [104]. In a recent study, it was shown that
coexpression of DcR1 and DcR2 with DR4/DR5 on the same
cell can block apoptosis. However, TRAIL was engineered in
order to escape from binding to DcRs, which were found to
still exert trans-cellular regulation originating from stromal
cells and affect tumor cells. Therefore, it is important to target
these decoy receptors selectively to gain maximum efficacy
[106]. Another recent study showed that DR4 and DR5 were
upregulated while DcR1 and DcR2 downregulated in colon
cancer cells after their treatment with a non-steroidal anti-in-
flammatory drug. Therefore, colon cancer cells became sensi-
tive to TRAIL-induced apoptosis [107]. The fifth TRAIL re-
ceptor is osteoprotegerin (OPG), which is a secreted receptor
for TRAIL with low affinity. OPG has sequence homology to
TNF receptor superfamily, however but lacks of a trans-
membrane domain. OPG can bind to TRAIL and prevents
its interaction with death receptors, thus preventing Jurkat
cells from undergoing TRAIL-mediated apoptosis [108].
Therefore, OPG has an anti-apoptotic effect by preventing
interaction between TRAIL and the death receptors [109].
Lane et al. (2012) [110] showed the relationship between
higher OPG expression and resistance of ovarian cancer cells
to TRAIL-induced apoptosis.
Similar to apoptosis induction by Fas/FasL, binding of
TRAIL to its DRs, DR4 and DR5 recruits the adaptor protein
FADD and inactive versions of caspase-8 and -10 to form the
DISC complex in which caspase-8 and -10 become activated
by auto-proteolytic cleavage and released in the cytosol to
activate effector caspases [111].
The size of human TRAIL gene is ~20 kb, containing five
exons and four introns. The first exon encodes for the trans-
membrane domain and the cytoplasmic domain, whereas
exons 4 and 5 code for the extracellular domain responsible
for the interaction of TRAIL with its receptors. Exon 5 also
encodes for the C-terminal amino acids along with containing
the 3′-untranslated region (3′-UTR) and poly-A tail [112].
There are various variants of TRAIL; however, only one spe-
cific isoform of TRAIL (TRAILα) is responsible for its
cancer-selective apoptosis induction potential [113].
TRAIL gene is subjected to strict regulation due to its crit-
ical role in the induction apoptosis. Altered expression of
TRAIL gene has been found in various kind of disease.
Multiple studies have been performed to analyze single-
nucleotide polymorphisms (SNPs) in various patient popula-
tions. In a recent study, peripheral blood samples were ana-
lyzed in terms of SNPs in TRAIL promoter and substitution of
C to Tat position -723was found to be significantly associated
with sporadic breast cancer and decreased TRAIL mRNA
levels due to transcriptional repression [114]. Bos et al.
(2009) found that TRAIL mRNA expression decreased
in breast cancer patients with brain metastasis [115].
TRAIL has been considered as a potential therapeutic tar-
get due to its selective apoptosis inducing action in cancer
cells as compared normal cells [116]. There are several ongo-
ing and completed clinical phase studies targeting TRAIL
apoptotic pathway by using agents including monoclonal an-
tibodies and recombinant human proteins, and these
studies are giving promising results with no significant toxic
effects [117].
TNF and TNF receptor 1–2 (TNFR1 AND TNFR2)
TNF is expressed as a trans-membrane 26-kDa protein and
then undergoes proteolytic cleavage to form 17-kDa trimeric
soluble cytokine. The resulting TNF functions by binding to
two different receptors, TNRF1 and TNFR2, which are also
trimeric trans-membrane proteins [90]. TNF is produced by
immune cells including activated natural killer cells, T cells,
and activated monocytes/macrophages and a wide range of
non-immune cells such as fibroblasts [118]. TNF/TNFR sig-
naling is well known to be involved in various cellular func-
tions such as apoptosis, cell proliferation, and differentiation
[119].
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TNF-mediated apoptosis is generally carried out by
TNFR1 (DR1), since only TNFR1 is known to contain DD
[87]. Binding of TNF to TNFR1 triggers the recruitment of
TRADD protein through its DD. Then, TRADD interacts with
FADD resulting in the recruitment of pro-caspase-8, which is
proteolytically cleaved to active caspase-8. Caspase-8 then
activates caspase-3 responsible for apoptotic cell death
[120]. The activity of caspase-8 is strictly regulated by a neg-
ative inhibitor protein cFLIP that contains DED instead of
DD. cFLIP interacts with pro-caspase-8 to prevent its contin-
uous recruitment to the TNFR1 DISC [121]. TNF-induced
cell death occurs only under stress conditions such as altered
cell metabolism, inhibition of cell cycle progression, and pro-
tein synthesis [120]. Therefore, it only induces apoptosis in
transformed cells (cancer cells), virus-infected cells, or
stressed cells, not in normal healthy cells. Interestingly,
TNFR2 has been shown to function in cell proliferation unlike
TNFR1 [122].
In a recent study, IL32-α, a novel cytokine, was found to
inhibit colon cancer cell growth in an experimentally generat-
ed colon cancer model by increasing TNFR1-induced cell
death signaling, which was evidenced by increased ex-
pression of TNFR1. Yu et al. [123, 124] found a new way of
apoptosis induction in adenosine-treated colon cancer cells,
which included increased expression of TNFR1. TNFα secre-
tion increased in acute myeloid leukemia cells after treatment
with SMACmimetic and IFNα combination [125]. Inhibition
of TNFα and TNFR1 by a pharmacological inhibitor and
genetic silencing, respectively, reduced SMAC mimetic/
IFNα-triggered apoptosis. Tao et al. suggested that survivin,
an inhibitor of apoptosis, inhibitor induced programmed cell
death in Wilms tumor cells by increasing expression of
TNFR1 signaling [126].
As well as TNFα, lymphotoxin α (LTα) which is secreted
as a homotrimer binds to TNRF1 [127]. Even though both
TNFα and LTα bind signal via TNFR1, LTα was found to
possess less ability to induce TNRF-mediated cell death in an
early study [128]. However, a recent research by Etemadi et al.
displayed that LTα has same potential to induce apoptosis via
TNFR1 signaling [129].
Genetic changes in the promoter region of TNFα have
beenwell studied in several human diseases to find correlation
between apoptosis induction and TNFα expression. De
Oliveria et al. studied the effect of a polymorphism, TNF-α-
857 C/T, on gastric cancer patients, found that this mutation
decreased mRNA level of TNFα resulting in resistance to
apoptosis [130].
Death receptor 3
Death receptor 3, also known as APO-3, has four characteris-
tic cysteine-rich motifs with molecular weight of 53.5 kDa.
Death receptor 3 (DR3) gene is localized on chromosome 1
and encodes a type II trans-membrane protein. Similar to other
TNFR family members, DR3 has a DD in its cytoplasmic part
and initiates apoptotic signaling [87].
Most of the studies have been related to DR3 involvement
in immune system modulation due to its frequent expression
on lymphoid tissues such as the spleen, thymus, and periph-
eral blood lymphocytes [131]. The role of DR3 in the devel-
opment of some human malignancies has also been enlight-
ened. DR3 expression was shown to be increased in human
colon cancer cells treated with cordycepin, a deoxy form of
adenosine, resulting in apoptosis induction [132]. A specific
phenolic compound triggered apoptosis in human non-small-
cell lung cancer (NSCLC) cells by increasing the expression
of DR3 [133]. Silencing of DR3 via siRNA approach reversed
its growth inhibitory effect.
p53
p53 is encoded by human TP53 gene localized on the short
arm of chromosome 17 with a molecular mass of 43.7 kDa
[134]. It occupies 19.200 bp including 11 exons. There are
various p53 isoforms based on alternative splicing of TP53
gene; some of which play opposite roles as compared to p53,
while others have similar functions like full-length p53 [135].
Human p53 protein is composed of the following three
different domains with important functions: the DNA-
binding domain, the N-terminal trans-activational domain,
and the C-terminal oligomerization domain [136]. DNA-
binding domain binds to response elements of target genes,
whereas the N-terminal trans-activation domain forms binding
sites for several negative or positive regulators. The C-
terminal domain undergoes alternative splicing and posttrans-
lational modifications [137].
p53 acts as tetrameric transcription factor, which controls
the expression of a large set of genes involved in significant
cellular processes including DNA damage detection, cell cy-
cle arrest, apoptosis, DNA repair, and senescence [134]. It is
both involved in intrinsic and extrinsic pathways of apoptosis
by inducing transcription of several proteins like PUMA, Bid,
Bax, TRAILR2, and CD95, which is called transcription-
dependent apoptotic pathway of p53 taking place in the nu-
cleus [138]. In this pathway of p53-dependent apoptosis, the
trans-activation domain of p53 interacts with the players of
basal transcription machinery such as the transcriptional coac-
tivator p300/CBP [139]. In normal healthy cells, p53 levels
are very low due to its rapid turnover; however, if a damage is
detected in the cells, p53 becomes stabilized resulting in-
creased p53 level [140]. p53 stability is controlled by mouse
double minute 2 (MDM2) gene, which is an E3 ubiquitin
ligase that negatively regulates p53 stability through
ubiquitination, thus proteosomal degradation. MDM2 also in-
hibits the interaction between the p53 trans-activation domain
and the components of transcription machinery [141]. MDM2
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has been found to be overexpressed in many cancer cells,
which leads to neutralization of interaction between p53 and
transcription machinery components, thus impairing
transcription-dependent apoptosis [142, 143].
p53 has the ability to activate intrinsic pathway of apopto-
sis by inducing the transcription of especially apoptotic Bcl-2
family genes such as PUMA [144]. p53 induces PUMA
mRNA expression immediately in response to DNA damage
by binding the two p53-responsive elements in the PUMA
promoter. p53 binding results in the acetylation of core his-
tones, H3 and H4, which is responsible for chromosome
decondensation and transcriptional activation [145].
Similarly, TRAIL-R2 expression is induced by p53, which
binds to a p53-responsive element in TRAIL-R2 promoter in
order to induce extrinsic pathway of apoptosis [140]. As an
alternative mechanism, p53 functions a transcriptional repres-
sor of certain anti-apoptotic genes including survivin which
promotes caspase activation [146]. p53 is also directly in-
volved in apoptosome formation by activating transcription
of Apaf-1 gene including a p53 response element in its pro-
moter [54]. In response to DNA damage, p53 is also displayed
to activate caspase-6 cleaving nuclear envelope protein lamin
A and various transcription factors through a response element
within the third intron of the gene [147].
As well as transcription-dependent functions of p53, its
transcription-independent functions in terms of apoptosis have
been defined. p53 induces apoptosis by acting directly at mi-
tochondria. p53 trans-locates to the mitochondria in response
to apoptotic signal, where it forms inhibitory complexes with
Bcl-XL and Bcl-2 causing the permeabilization of the mito-
chondrial membrane and cytochrome c release [148]. The
interaction between p53 and Bcl-XL and Bcl-2 is mediated
by p53 trans-activation domain like p300/CBP binding, even
though these two modes of p53-dependent apoptosis induc-
tion occur in different cellular compartments [149]. Moreover,
cytosolic p53 might induce the activation of pro-apoptotic
Bax via direct protein-protein interactions [150]. Leu et al.
displayed that p53 interacts with pro-apoptotic mitochondrial
membrane protein Bak, which makes Bak undergo oligomer-
ization and releases cytochrome c frommitochondria. Binding
of p53 to Bak damages interaction between Bak and anti-
apoptotic Mcl-1 [151].
Mutations in p53 gene have been considered most common
genetic changes in cancer. Mutant p53 proteins can both lose
their native tumor suppressor activity and provide active tu-
mor development [152]. Missense mutations form the major-
ity of alterations in p53 gene, which commonly occur in the
DNA binding domain of p53, thus preventing p53 from pro-
moting target gene expression [153]. Recently, Saleem et al.
analyzed loss of function mutations in p53 gene in the patients
of oral squamous cell carcinoma and found that AGT to ACT
missense mutation in DNA binding domain may result in
impaired p53 function. In chronic lymphocytic leukemia
patients, missense mutations in DNA binding motif were cor-
related with poor survival [154, 155].
p53 has been considered as a significant player of apoptosis
in many studies, and there is a growing accumulation of arti-
cles revealing its role in many malignancies. In a recent study
byWang et al., acute pro-myelocytic leukemia cells were sub-
jected to apoptosis when treated with combination of
tetraarsenictetrasulfide and arsenic trioxide through upregula-
tion of p53 and its target gene Bax. Transcription-independent
role of p53 in apoptosis induction was identified in a study in
which p53 trans-located to mitochondria and induced mito-
chondrial membrane depolarization in HUVEC cells exposed
to heat stress [156, 157].
There is an increasing attention to develop different strate-
gies that can modulate p53-dependent apoptotic pathways
such as inhibition of p53-MDM2 interaction using MDM2
inhibitors, restoring mutated p53 back to its wild-type form
and p53 vaccines [158–160].
MicroRNAs in extrinsic and intrinsic apoptotic pathways
Changes in the apoptotic response in cancer can result in tu-
mor initiation, progression, and treatment resistance [3]. There
are numerous studies including the roles of microRNAs in the
control of apoptosis, and these microRNAs display their ef-
fects by directly targeting genes involved in both extrinsic and
intrinsic pathways of apoptosis [161]. These microRNAs
(miRNAs) can be classified as oncogenic and tumor suppres-
sive miRNAs [162]. One of these miRNAs is miR-130a that
was found to reduce drug resistance in non-small-cell lung
cancer by targeting MET proto-oncogene and to sensitize this
cancer cells to TRAIL-induced apoptosis by inhibiting miR-
221 and miR-222, which are upregulated by MET and in-
volved in TRAIL resistance [163]. Therefore, miR-221 and
miR-222 are oncogenic miRNAs that induce drug resistance
and block apoptosis in several cancer types such as gliomas
[164]. Another oncogenic miRNA exerting its anti-apoptotic
effects by inhibiting FasL directly is miR-21, which is found
to be upregulated in advanced pancreatic cancer patients
[165]. miR-24 regulates apoptosis by binding to coding se-
quence of Fas-associated factor 1 (FAF1) mRNA and induced
apoptosis of several different types of cancer [166]. miR-21
also negatively regulates PTEN, a tumor suppressor gene,
involved in the apoptotic pathway through the formation of
DISC complex in many tumors such as breast and gastric
cancers [167, 168]. In gastric cells, miR-21 upregulated and
decreased PTEN expression, resulting in significant suppres-
sion of trastuzumab-induced apoptosis [168]. miR-200c sen-
sitized cells to apoptosis by directly targeting Fas-associated
phosphatase-1 (FAP-1), which is an inhibitor of Fas-induced
apoptosis [169]. miRNA-886-5p inhibited apoptosis of hu-
man cervical cancer cells by downregulating Bax [170].
Zhou et al. (2010) [171] found that miR-125bwas upregulated
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in taxol-resistant breast cancer cells and suppressed apoptosis.
Bak1, pro-apoptotic Bcl-2 antagonist killer 1, was identified
as the direct target of miR-125b. miR-25 and miR-32 could
directly target the pro-apoptotic function of Bim, therefore
suppressing apoptosis in ovarian and human myeloid leuke-
mia cells, respectively [172, 173]. In addition, miR-483-3p
might target PUMA, whose enforced expression protects cells
from apoptosis [174]. miR-34 decreases the expression of Bcl-
2, resulting in an increase in apoptosis [175]. In this study,
downregulation of miR-34 induced cell proliferation and in-
vasion in malignant mesothelioma. miR-15b/16 could down-
regulate Bcl-2, thereby triggering apoptosis [176]. miR-153
induced apoptosis of glioblastoma cells by targeting 3′-UTR
of Bcl-2 and Mcl-1 [177]. miR-491 could induce apoptosis in
colorectal cancer cells by downregulating anti-apoptotic Bcl-
XL [178]. There are several studies showing the roles of
miRNAs in the regulation of caspase expression. miR-23a
and miR-24a blocked mitochondrial apoptosis by inhibiting
the expression of caspase-9 [179, 180]. The downregulation of
miR-23a increased the 5-FU-induced apoptosis in colon can-
cer cells [179]. Wu et al. (2014) [181] displayed that miR-421
upregulated in human gastric cell lines and tissues. miR-421
downregulated the expression of caspase-3 and blocked the
apoptosis of cancer cells. miR-106b-25 was shown to be up-
regulated in human prostate cancer and functions by partly
inhibiting of caspase-7 expression [182]. Floyd et al. (2014)
[183] demonstrated that miR-582-5p and miR-363 inhibit ap-
optosis by directly targeting caspase-3 and caspase-9 in glio-
blastoma. Caspase-3 has been shown to be a target of miR let-
7a in human squamous carcinoma cells and hepatocellular
carcinoma cells [184]. Curcumin induced apoptosis of
NSCLC by the downregulation of miR-186, whose direct tar-
get is caspase-10 [185]. Based on all this evidence discussed
in this particular review, miRNAs play key regulatory roles in
apoptosis and could be important therapeutic targets in cancer
(Fig. 2).
Bioactive sphingolipids in apoptotic pathways
Bioactive sphingolipids are a family of membrane lipids that
have many regulatory roles in several cellular events such as
cell proliferation, senescence, adhesion, migration, and also
apoptosis [186]. Ceramide, the central molecule of bioactive
sphingolipid metabolism, was reported as a regulator of apo-
ptosis in many studies. Treatment of cancer cells with radia-
tion and chemotherapeutics such as vincristine, daunorubicin,
gemcitabine, and etoposide result in ceramide accumulation in
the cells as a secondary effect of these therapeutics [187].
Decreased ceramide levels result in the development of drug
resistance in cancer cells [188]. In vitro studies indicated that
treatment of cancer cells with ceramide triggers the release of
cytochrome-c from the mitochondria [189]. Additionally, it
was reported that anti-apoptotic Bcl-2 blocks ceramide chan-
nels in an independent manner from Bak and Bax [190].
Furthermore, ceramide also induces Bax-mediated apoptosis
in several types of cancer including, breast, prostate, and colon
cancers [191]. Ceramide was reported that it activates cathep-
sin D, an inducer of apoptosis in a form of lysosomal aspartyl
protease, in response to gemcitabine treatment [192]. Unlike
ceramide, the other member of sphingolipid family, sphingo-
sine 1-P (S1P) is related to cell proliferation, survival, and also
inhibition of apoptosis [193]. S1P was reported to cause
Fig. 2 miRNAs involved in the
apoptotic pathways. Some of the
miRNAs can inhibit apoptosis by
targeting the death-receptor
pathway including miR-21,
miR-24, and miR-200c. In the
mitochondrial pathway, various
miRNAs could target Bcl-2
family proteins and caspases
including miRNA-886-5p,
miR-125b, miR-25, miR-32,
miR-483-3p, miR-34, miR-15b/
16, miR-153, miR-491, miR-23a
and miR-24a, miR-421,
miR-106b-25, miR-582-5p and
miR-363, miR let-7a, and
miR-186
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angiogenesis by VEGF signaling, which then triggers RAS
and MAPK signaling in cancer cells. By this way, S1P causes
cytoskeleton reconstruction and apoptosis inhibition [194].
While increased ceramide levels cause induction of apoptosis,
increased S1P levels cause inhibition of apoptosis [195]. S1P
leads to drug resistance due to its anti-apoptotic function.
Sphingosine kinase-1 (SK1), which catalyzes the conversion
of apoptotic ceramide to anti-apoptotic S1P, was also reported
to decrease apoptotic effects of chemotherapeutic agents in
prostate cancer [196]. Like S1P, glucosylceramide (GC), the
other important member of sphingolipid family, is also known
as a powe r f u l an t i - a pop t o t i c mo l e cu l e [ 193 ] .
Glucosylceramide synthase (GCS), the enzyme catalyzing
the conversion of apoptotic ceramide to anti-apoptotic GC,
was found to be increased in drug-resistant cancer cells
[193]. Treatment of pancreatic cancer cells with a ceramide
analogue causes the accumulation of ceramide in the mito-
chondria, and by this way, ceramide reduces drug resistance
and triggers apoptosis [197]. Additionally, treatment of pan-
creatic cancer cells with ceramide in combination with a GCS
inhibitor, PDMP, decreases tumor growth in vivo [198].
Moreover, GC degradation increases ceramide generation
resulting in the trigger of apoptosis and also reduced tumor
growth in melanoma xenografts [199]. Reduced tumor growth
was also reported in mouse models with breast cancer treated
with C6:ceramide [200]. Furthermore, a type of sphingosine
kinase inhibitor, SK2, was reported to trigger apoptosis, inhib-
it cell proliferation, and decrease tumor size in mouse models
bearing hepatoma, mammary adenocarcinoma, and kidney
carcinoma [201, 202]. Safingol, the first agent used in the
clinic due to its ability in sphingosine kinase inhibition, in-
creases apoptotic effects of chemotherapeutics used in cancer
therapy [203]. An FDA-approved drug that has inhibitory ef-
fects on SK1 and SK2 activities, FTY720, inhibits cell prolif-
eration and leads to apoptosis in mice bearing breast cancer or
melanoma [204]. In chronic myeloid leukemia (CML) cell
lines, increase in serine palmitoyltransferase levels via BCR/
ABL inhibition result in activation of apoptotic signals [205].
GCS inhibition in CML cell lines bearing T315I mutation
results in apoptosis via activating GSK-3 [206]. Another study
reported that ceramide triggers apoptosis via activating p38,
caspase-8, and c-Jun N-terminal kinase (JNK) in K562 CML
cells [207]. Many studies from our laboratory also showed
effects of bioactive sphingolipids on apoptosis. In K562
CML cell lines resistant to nilotinib, apoptotic ceramide
synthase-1 and Bax genes were found to be downregulated
while anti-apoptotic SK1 and GCS genes were overexpressed,
and inhibition of these overexpressed genes sensitized the
cells against nilotinib treatment [208]. Our studies also
showed that when we overexpress GCS in imatinib-sensitive
K562 cells, the cells developed resistance against the drug via
inhibiting apoptosis. Inhibition of GCS and SK1 triggered
apoptosis via leading to ceramide accumulation in imatinib-
resistant and imatinib-sensitive K562 CML cell lines [209].
Additionally, when we treated K562 human CML cell lines
and HL60 human acute pro-myelocytic leukemia cell lines
with resveratrol in combination with ceramide analog,
GCS inhibitor, or SK1 inhibitor, apoptotic effects of res-
veratrol increased synergistically in the cells treated with
resveratrol and ceramide combination, while the cells treat-
ed with resveratrol and GCS or SK1 combinations resisted
to apoptosis as compared to the control group [210, 211].
Furthermore, our studies also showed that GCS and SK1
inhibition in combination with nilotinib or dasatinib treat-
ment synergistically triggers apoptosis in K562 and Meg01
human CML cell lines [212, 213].
Briefly, while ceramide is a powerful apoptotic molecule,
glucosylceramide and S1P generated from ceramide by GCS
and SK1 activities, respectively, are powerful anti-apoptotic
molecules, and therefore, alterations in intracellular levels of
these sphingolipids could be a novel approach for cancer
therapy.
Summary and perspectives
Apoptosis is highly regulated way of cell death, which is
crucial for all higher-level organisms to balance tissues
homeostasis and control cell proliferation as well as re-
move damaged or unnecessary cells. Apoptosis has its
own morphological and biochemical properties where
caspases play a central role at the end. Here, we have fo-
cused on aspects of apoptosis in terms of critical genes and
their products together with their role in both intrinsic and
extrinsic pathways of apoptosis. In this specific vital pro-
cess, diverse groups of molecules function compatibly for
strict regulation. Any alterations or abnormalities occur-
ring in apoptotic processes contribute to development of
human diseases and malignancies especially cancer. Deep
understanding of apoptotic signaling mechanisms, individ-
ual players, and genes involved in apoptosis have provided
a great opportunity to develop novel agents that make ap-
optosis deficient cells sensitive to apoptosis.
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